Filtros de búsqueda

Lista de obras de Richard F. Kefford

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

artículo científico publicado en 2012

10q deletions in metastatic cutaneous melanoma

artículo científico publicado en 1998

A melanoma-associated germline mutation in exon 1beta inactivates p14ARF.

artículo científico publicado en 2001

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

artículo científico publicado en 2014

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

artículo científico publicado en 2011

A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma

article

A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

artículo científico publicado en 2006

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

artículo científico publicado en 1989

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

artículo científico

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.

artículo científico publicado en 2014

Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.

artículo científico

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

artículo científico publicado en 2015

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

artículo científico publicado en 2013

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

artículo científico publicado en 2012

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

artículo científico publicado en 2016

Acute Radiation Skin Toxicity Associated With BRAF Inhibitors

artículo científico publicado en 2014

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

artículo científico publicado en 2017

Adjuvant therapy of cutaneous melanoma: the interferon debate.

artículo científico publicado en 2003

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

scientific article published on 29 November 2019

Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds

article

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

artículo científico publicado en 2013

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

artículo científico publicado en 2015

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

artículo científico publicado en 2018

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure

artículo científico publicado en 2019

Australian doctors and nuclear war

artículo científico publicado en 1982

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.

artículo científico publicado en 2016

BRAF inhibitor activity in V600R metastatic melanoma--response.

artículo científico publicado en 2013

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

artículo científico publicado en 2014

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

artículo científico publicado en 2012

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.

artículo científico publicado en 2013

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas

artículo científico publicado en 1999

Cancer in the family. Guidelines for general practice

artículo científico publicado en 1997

Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly

artículo científico publicado el 1 de febrero de 1992

Causes of deaths in an oncology unit

artículo científico publicado en 1981

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

artículo científico publicado en 2016

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

artículo científico publicado en 2014

Chemotherapeutic induced fascial oedema.

artículo científico publicado en 2005

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy

article

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

artículo científico publicado en 2017

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

artículo científico publicado en 2009

Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.

artículo científico publicado en 2012

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

artículo científico publicado en 2017

Clinicians' attitudes to oncology clinical practice guidelines and the barriers and facilitators to adherence: a mixed methods study protocol

artículo científico publicado en 2020

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

artículo científico publicado en 2015

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

artículo científico publicado en 2014

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

artículo científico publicado en 2012

Common sequence variants on 20q11.22 confer melanoma susceptibility

artículo científico publicado en 2008

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

artículo científico publicado en 2014

Conservation and Potential Role of RNA-Instability Motifs in Urokinase Gene 3'-Untranslated Sequences ⬇️

artículo científico publicado el 7 de agosto de 1991

Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer

scientific article published on 01 October 1995

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.

artículo científico publicado en 2015

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

artículo científico publicado en 2014

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.

artículo científico publicado en 2016

Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks

artículo científico publicado en 2014

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

artículo científico publicado en 2012

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

artículo científico publicado en 2012

Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-mb interval

article

Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes

article

Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells.

artículo científico publicado en 1993

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

artículo científico publicado en 2014

Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.

artículo científico publicado en 1997

Diffuse melanosis cutis in the setting of BRAF(V600E) mutant melanoma and treatment with targeted therapies.

artículo científico publicado en 2014

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

artículo científico publicado en 2019

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

scientific article published on 24 April 2012

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring--The TADE Study

article

Drug treatment for melanoma: progress, but who pays?

artículo científico publicado en 2012

Drug treatment for melanoma: progress, but who pays? Comment

artículo científico publicado en 2012

Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix

artículo científico publicado en 1992

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

artículo científico publicado en 2017

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

artículo científico publicado en 2017

Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment

artículo científico publicado en 2014

Early-life sun exposure and risk of melanoma before age 40 years

article

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression

artículo científico publicado en 2013

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

artículo científico publicado en 2017

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline mutations

artículo científico publicado en 2018

Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis.

artículo científico publicado en 2005

Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer

artículo científico publicado en 1990

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

Evaluation of commercial kits for purification of circulating free DNA

scientific article published on 29 August 2018

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

artículo científico publicado en 2014

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

artículo científico publicado en 2017

Excerpts from the report of the chairman, Australian branch of MAPW annual general meeting, 16 Oct 1982

artículo científico publicado el 1 de junio de 1983

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma

artículo científico publicado en 2013

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

artículo científico publicado en 2015

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

artículo científico publicado en 2014

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents

artículo científico publicado en 2006

Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma

artículo científico publicado en 2013

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

artículo científico publicado en 2019

Flow cytometric analysis of adenosine analogue lymphocytotoxicity

artículo científico publicado en 1983

Frequent loss of heterozygosity targeting the inactive X chromosome in melanoma

article

Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.

artículo científico publicado en 2001

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

artículo científico publicado en 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

artículo científico publicado en 2014

G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine

artículo científico publicado en 1981

Genetic testing for melanoma.

artículo científico publicado en 2002

Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3

scientific journal article

Genome-wide association study identifies three loci associated with melanoma risk

scientific article published on 05 July 2009

Genome-wide association study identifies three new melanoma susceptibility loci

artículo científico publicado en 2011

Health-care interpreters and cancer

artículo científico publicado en 1989

High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL

article

Hypertrophic osteoarthropathy from pulmonary metastatic phyllodes tumour of the breast

artículo científico publicado en 2004

IGFBP7 is not required for B-RAF-induced melanocyte senescence

artículo científico publicado en 2010

Identification of a melanoma susceptibility locus and somatic mutation in TET2.

artículo científico publicado en 2014

Immune checkpoint inhibitors in melanoma

artículo científico publicado en 2015

Immunoblastic lymphoma in husband and wife.

artículo científico publicado en 1980

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma

artículo científico publicado en 2013

Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.

artículo científico publicado en 2013

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

artículo científico publicado en 2013

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

artículo científico publicado en 2014

Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin

artículo científico publicado en 1998

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

scientific article published on 06 January 2014

Interferon Signaling Is Frequently Downregulated in Melanoma

artículo científico publicado en 2018

Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.

artículo científico publicado en 1993

Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study

scientific article published on 01 October 1980

Intranuclear post-transcriptional down-regulation responsible for loss of a keratin differentiation marker in tumour progression

artículo científico publicado en 1995

Intrapatient homogeneity of BRAFV600E expression in melanoma.

artículo científico publicado en 2014

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

artículo científico publicado en 2012

Intravascular metastatic melanoma: a difficult diagnosis

artículo científico publicado en 2013

Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series

artículo científico

Is there a role for genetic testing in patients with melanoma?

artículo científico publicado en 2003

Isolation and preliminary characterisation of an X-ray-sensitive mammalian mutant cell line (WMXRS-1).

artículo científico publicado en 1994

Linkage analysis of familial melanoma and chromosome 6 in 14 Australian kindreds ⬇️

artículo científico publicado el 1 de agosto de 1997

Liquid biomarkers in melanoma: detection and discovery.

artículo científico publicado en 2018

Localization of a novel melanoma susceptibility locus to 1p22

artículo científico publicado en 2003

Locally advanced and inflammatory breast cancer.

artículo científico publicado en 2005

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

artículo científico publicado en 2017

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

scientific article published on 01 January 2020

Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy.

artículo científico publicado en 2008

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma

article

Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma.

artículo científico publicado en 1994

Loss of heterozygosity in malignant melanoma at loci on chromosomes 11 and 17 implicated in the pathogenesis of other cancers

artículo científico publicado en 1993

Loss of keratin expression in anaplastic carcinoma cells due to posttranscriptional down-regulation acting in trans

artículo científico publicado en 1992

MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study

artículo científico publicado en 2013

MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study

artículo científico publicado en 2012

Medical heat for climate change.

artículo científico publicado en 2006

Melanoma - a management guide for GPs

artículo científico publicado en 2012

Melanoma management in 2007.

artículo científico publicado en 2007

Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK

article

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

artículo científico publicado en 2012

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

artículo científico publicado en 2017

Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors

artículo científico publicado en 2019

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma

artículo científico publicado en 2005

Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells.

artículo científico publicado en 1999

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

scientific article published on 03 June 2019

Neoadjuvant systemic therapy for breast cancer: the Westmead experience

artículo científico publicado en 2017

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma

artículo científico publicado en 2014

Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma

artículo científico publicado en 2012

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

scientific article published on April 2009

Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.

artículo científico publicado en 2009

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion

artículo científico publicado en 2012

Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes

scientific article published on 06 May 2010

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

scholarly article by Mal Irvine published in September 2018

Oncogenic signaling in uveal melanoma

artículo científico publicado en 2018

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

artículo científico publicado en 2016

Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

artículo científico publicado en 1982

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

artículo científico publicado en 2014

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

artículo científico publicado en 2016

PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.

artículo científico publicado en 2016

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

artículo científico publicado en 2017

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

artículo científico publicado en 2015

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

article

Paradoxical oncogenesis: are all BRAF inhibitors equal?

artículo científico publicado en 2013

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

scientific article published on 27 March 2019

Patterns of metastases in familial and non-familial melanoma

artículo científico publicado en 2003

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib

artículo científico publicado en 2013

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.

artículo científico publicado en 2016

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

artículo científico publicado en 2017

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

artículo científico publicado en 2012

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Resear

artículo científico publicado en 2017

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

artículo científico publicado en 2013

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

artículo científico publicado en 2012

Pneumocystis jirovecii in a patient on dose-dense chemotherapy for early breast cancer

scientific article published on 05 July 2019

Poly(A)+RNA as a Possible Target for Deoxyadenosine Induced G1/G0 Lymphotoxicity

artículo científico publicado en 1984

Population-based, case-control-family design to investigate genetic and environmental influences on melanoma risk: Australian Melanoma Family Study

artículo científico publicado en 2009

Post-transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BC1 rat mammary tumor cells

artículo científico publicado el 1 de abril de 1992

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

artículo científico publicado en 2019

Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.

artículo científico publicado en 2010

Prediction of life-expectancy in hospice patients: identification of novel prognostic factors.

artículo científico publicado en 1993

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

artículo científico publicado en 2012

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

artículo científico publicado en 2014

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom

artículo científico publicado en 2014

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

artículo científico publicado en 2011

Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma

artículo científico publicado en 1993

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Pulmonary toxicity associated with bleomycin

article

Purine deoxynucleoside toxicity in nondividing human lymphoid cells

article

Purinogenic lymphocytotoxicity: Clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors

artículo científico publicado en 1983

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

artículo científico publicado en 2007

Reply to E. Hindié and K.R. Hess

artículo científico publicado en 2019

Reply to K.S. Wilson et al

scientific article published on 01 August 2013

Reply to M. Perier-Muzet et al

scientific article published on 02 September 2014

Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.

artículo científico publicado en 2016

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

article

S-adenosylhomocysteine hydrolase inhibition in deoxyadenosine-treated human T-lymphoblasts and resting peripheral blood lymphocytes

artículo científico publicado en 1982

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

artículo científico publicado en 2013

Selection criteria for genetic assessment of patients with familial melanoma

artículo científico publicado en 2009

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

artículo científico publicado en 2011

Selective loss of wild-type p16(INK4a) expression in human nevi

artículo científico publicado en 2011

Sentinel node biopsy for melanoma: The medical oncology perspective

Serum beta 2-microglobulin binds to a T-cell differentiation antigen and increases its expression.

artículo científico publicado en 1984

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

artículo científico

Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma

artículo científico publicado en 2011

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

artículo científico publicado en 2014

Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia

artículo científico publicado en 2017

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

artículo científico publicado en 2012

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients

artículo científico publicado en 2014

Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling

artículo científico publicado en 2014

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

artículo científico publicado en 2019

Targeting BRAF for patients with melanoma.

artículo científico publicado en 2011

Targeting molecular mechanisms in cancer.

artículo científico publicado en 2002

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

artículo científico

Terminal incorporation of 2'-deoxyadenosine into polyadenylate segments of polyadenylated RNA in G1-phase-arrested human T-lymphoblasts.

artículo científico publicado en 1983

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

artículo científico publicado en 2012

The WDNM1 gene product is a novel member of the 'four-disulphide core' family of proteins

artículo científico publicado en 1991

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a

artículo científico publicado en 2009

The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired

artículo científico publicado en 2005

The molecular profile of metastatic melanoma in Australia

artículo científico publicado en 2016

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

artículo científico publicado en 2014

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence

artículo científico publicado en 2009

The spectrum of in vitro radiosensitivity in four human melanoma cell lines is not accounted for by differential induction or rejoining of DNA double strand breaks.

artículo científico publicado en 1995

Treatment algorithms in stage IV melanoma

artículo científico

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

artículo científico publicado en 2013

Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization.

artículo científico publicado en 2000

Unregulated and Independent Expression of Collagenase and Transin Related to Tumor Progression

artículo científico publicado en 1993

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

artículo científico publicado en 2016

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility

artículo científico publicado en 2018

Whole-genome landscapes of major melanoma subtypes.

artículo científico publicado en 2017

Wild type and melanoma-associated mutant p16INK4aproteins do not oligomerize in vivo

artículo científico publicado en 2009

X inactivation, DNA deletion, and microsatellite instability in common acquired melanocytic nevi

artículo científico publicado en 2001

bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays

scientific article published on 01 April 2019

p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners.

artículo científico publicado en 2005

p14ARF regulates E2F-1 ubiquitination and degradation via a p53-dependent mechanism.

artículo científico publicado en 2007

p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes

artículo científico publicado en 2013

p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors

artículo científico publicado en 2008

p16INK4a-induced senescence is disabled by melanoma-associated mutations

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda